• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (GRADUAL-1) of Bofanglutide (GZR18) injection in Chinese Patients with Overweight or Obesity
    Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (GRADUAL-1) of Bofanglutide (GZR18) injection in Chinese Patients with Overweight or Obesity
    Date:2024-12-30

    Beijing, China, December 30, 2024 – Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) announced that the first participant has been successfully dosed in a Phase 3 clinical trial (GRADUAL-1) of Bofanglutide (research code: GZR18), a glucagon-like peptide-1 receptor agonist (GLP-1RA) bi-weekly formulation independently developed Gan & Lee, in Chinese partcipants with overweight or obesity. This marks the formal initiation of the first GLP-1 RA biweekly formulation for the indication of overweight or obesity into Phase 3 clinical development globally.

     

    This Phase 3 clinical trial was designed to evaluate the efficacy and safety of Bofanglutide injection in Chinese adults with overweight or obesity whose weight was inadequately controlled by diet and exercise (ClinicalTrials.gov registration number: NCT06728124). The study plans to enroll 630 subjects who will be randomly assigned to receive treatment of either 24 mg of Bofanglutide bi-weekly, 48 mg of Bofanglutide bi-weekly, or placebo. The primary endpoints include the percentage change in body weight from baseline and the proportion of subjects with 5% or more body weight loss from baseline.

     

    Previously, a Phase 2 study (NCT06256562) of Bofanglutide injection in Chinese subjects with overweight or obesity showed that after 30 weeks of treatment, the mean percentage in boday weight reduction from baseline was ?14.3% in the bi-weekly 24 mg group and ?17.3% in the bi-weekly 48 mg group. Additionally, Bofanglutide significantly reduced waist circumference and BMI, improved cardiovascular and glucose metabolism indicators, and demonstrated good safety and tolerability, with a safety profile similar to other GLP-1 receptor agonists.

     

    Professor Linong Ji from Peking University People's Hospital, the leading principal investigator of the GRADUAL-1 study, stated, "Obesity has become a critical global public health issue and is rapidly spreading in China. According to Chinese standards, nearly half of the population is currently in the obesity (BMI ≥28 kg/m2) or overweight (24 kg/m2 ≤ BMI <28 kg/m2) condition. By 2030, this proportion is expected to rise to 63%1. Obesity is not only a significant risk factor for diabetes and cardiovascular diseases but also places a substantial economic burden on society. Currently, many weight-loss medications require frequent injections, causing inconvenience to patients who generally prefer oral medications or therapies with lower dosing frequencies. Bofanglutide, as a bi-weekly GLP-1 RA, demonstrated remarkable weight-loss efficacy in Phase 2 clinical trials, along with improvements in fasting blood glucose, blood pressure, lipids, and other metabolic indicators, as well as overall safety and tolerability. I look forward to further confirming the efficacy and safety of Bofanglutide in Phase 3 trials to provide robust evidence for its market approval."


    About Gan & Lee

    Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

     

    In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 国产成人精品999在线| 朝桐光亚洲专区在线中文字幕| 强开小娟嫩苞又嫩又紧| 国产一区二区在线视频| 久久久久久久蜜桃| 阿v天堂2020| 无翼乌r18无遮掩全彩肉本子| 国产乱妇无码大黄aa片| 久久久国产99久久国产久| 超碰97久久国产精品牛牛| 日日夜夜操操操| 四虎影院国产精品| 丁香婷婷六月天| 精品久久人人妻人人做精品 | 厨房切底征服岳完整版| 中国一级片在线观看| 精品国产污污免费网站入口| 娇小体积女大战两黑鬼| 伊人激情久久综合中文字幕| 99久久久国产精品免费蜜臀| 欧美综合成人网| 国产精品亚洲а∨无码播放麻豆 | 国产成人精品2021| 久久精品一区二区三区四区| 色视频在线观看视频| 性满足久久久久久久久| 伊人久久大香线蕉综合网站| 91精品手机国产免费| 欧美三级在线看| 国产初次破初视频情侣| 中国一级黄色片子| 男生和女生一起差差差很痛的视频 | 日韩在线视频免费| 国产suv精品一区二区6| аⅴ中文在线天堂| 国产鲁鲁视频在线播放| 日本边添边摸边做边爱喷水| 又黄又爽一线毛片免费观看| www视频在线观看| 欧美成人香蕉网在线观看| 国产成人一区二区三区电影网站 |